{Extract}
(...)
A Poultry Farm in the Santarém Region.
(...)
Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8014
____
Media Monitoring for Signals about Emerging Threats
{Extract}
(...)
A Poultry Farm in the Santarém Region.
(...)
Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8014
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Extract}
(...)
{Northern Ireland}
Over 23k, 40 week-old layer hens. Positive test for HPAI H5N1, clinical signs presented prior to testing.
(...)
Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8010
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Extract}
(...)
A(H5) detections in the past week
Time Period: November 08, 2026 - November 14, 2026
-- A(H5) Detection: 15 site(s) (3.2%)
-- No Detection: 456 site(s) (96.8%)
-- No samples: 146 site(s)
___
(...)
Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/wastewater/emerging-viruses/h5.html?
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Extract}
(...)
National situation summary since 2024
° Person-to-person spread: None
§ There is no known person-to-person spread at this time.
° Current public health risk: Low
§ The current public health risk is Low.
° Cases in the U.S.: 75 cases {+1 in Oregon}
° Deaths in U.S.: 3 deaths {0}
(...)
Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/situation-summary/?CDC_AAref_Val=https://www.cdc.gov/flu/avianflu/avian-flu-summary.htm
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Extract}
(...)
Novel Influenza A Virus Infections
° One confirmed human infection with influenza A(H5) virus was reported to CDC this week.
§ To date, human-to-human transmission of influenza A(H5) virus has not been identified in the United States.
° The case was reported by the Oregon Health Authority and occurred in a worker aged ≥18 years at a commercial dairy cattle farm where highly pathogenic avian influenza (HPAI) A(H5) virus has been detected in cows.
§ This individual developed eye irritation during the week ending November 15, 2026 (Week 45), which they reported to the local health department.
§ Specimens were collected from the individual and tested at the state public health laboratory where a conjunctival specimen tested presumptive positive for influenza A(H5) virus using the CDC influenza A(H5) assay.
§ Influenza A(H5) virus was confirmed at CDC. This is the first influenza A(H5) case associated with a dairy worker in Oregon.
° There has been a total of four influenza A(H5) cases in dairy workers reported in 2026.
° Notification to WHO of this case was completed per International Health Regulations (IHR). More information regarding IHR can be found at http://www.who.int/topics/international_health_regulations/en/.
° The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/position_statements_files_2023/24-ID-09_Novel_Influenza_A.pdf.
° An up-to-date human case summary during the 2024 outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.
° Information about avian influenza is available at https://www.cdc.gov/bird-flu/.
° Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html.
° The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.
(...)
Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-45.html
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Summary}
(...)
Key Points
° Multiple seasonal influenza surveillance indicators continue to increase nationally.
° Many surveillance indicators are higher than typically observed at this time of year, but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater severity overall.
° During Week 45 (the week ending November 14, 2026), of the 613 influenza viruses reported by public health laboratories, 608 were influenza A and 5 were influenza B. Of the 365 influenza A viruses subtyped, 352 (96.4%) were influenza A(H1N1)pdm09, 12 (3.3%) were A(H3N2), and 1 (0.3%) was A(H5).
° Since Week 21 (the week ending May 30, 2026), 84.8% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been HA subclade E (newly designated alias of D.3.1.1).
° The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have circulated globally since. Influenza viruses are constantly changing, often requiring updates to influenza vaccines every season.
° Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. This week, recently circulating influenza A(H1N1)pdm09 viruses which were previously designated D.3.1.1 HA subclade have been reclassified into subclade E (with newly designated HA subclades E.1 to E.4), each with different combinations of genetic changes in their HA genes.
° It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season. So far, almost all the influenza viruses collected and antigenically characterized in the U.S. since Week 21 are antigenically similar to their respective influenza vaccine reference viruses based on CDC laboratory assays.
° Two pediatric deaths associated with season influenza virus infection occurring during the 2026-2027 influenza season were reported to CDC this week for a total of seven deaths this season.
° Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.
° The preliminary in-season severity assessment has classified the severity of influenza activity at this point in the season as low across all ages and all age groups. The severity assessment for the season changes with flu activity.
° CDC estimates that there have been at least 3,700,000 illnesses, 50,000 hospitalizations, and 2,800 deaths associated with flu so far this season.
° CDC’s FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits due to flu for the week ending November 28. The number of new flu hospital admissions is forecast to range from 9,200 to 36,100 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1.7% to 7.6%.
° Annual seasonal flu vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now. Influenza vaccination coverage estimates and influenza vaccine doses distributed for this season are available in FluVaxView.
° There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.1
° One confirmed human case of avian influenza A(H5) virus infection was reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.
° Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.
(...)
Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-45.html
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Extract}
(...)
Three Wild Mute Swans in the Zachodniopomorskie Region.
(...)
Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8009
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Exract}
(...)
A wild bird of unspecified species in the Jeollanam-do Region.
(...)
Source: World Animal Health Organization, https://wahis.woah.org/#/in-review/8006
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Extract}
(...)
Event data
As of 4pm AEST, 19 November 2026, Australia has 745 confirmed events of H5 bird flu in wildlife.
§ 10 in Western Australia (WA)
§ 344 in South Australia (SA)
§ 86 in New South Wales (NSW)
§ 2 in Queensland (QLD)
§ 249 in Victoria (VIC)
§ 53 in Tasmania (TAS)^
§ 1 in Other Territories#
{^} Includes events on Macquarie Island
{#} Jervis Bay Territory (Commonwealth jurisdiction)
(...)
Source: Australian Department of Agriculture, https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
November 19, 2026
H5 bird flu found in individual linked to Morrow County dairy farm
PORTLAND, Ore. – Oregon Health Authority has confirmed the state’s first human case of highly pathogenic avian influenza (HPAI) of 2026.
The individual’s infection is linked to an outbreak among cattle at a Morrow County dairy farm.
Epidemiologists at OHA’s Public Health Division received confirmation of the human HPAI case from the Oregon State Public Health Laboratory on Nov. 18.
They have been working closely with the Oregon Department of Agriculture (ODA) and Morrow County Public Health on the outbreak.
ODA provides PPE and training in its use to affected farm workers during an outbreak, while public health monitors exposed individuals.
After developing mild symptoms of HPAI, the affected individual was promptly treated with the antiviral medicine oseltamivir and tested.
They did not require hospitalization.
Morrow County public health officials have also offered oseltamivir to members of the individual’s household out of an abundance of caution.
The virus is not known to spread human-to-human.
Risk to the public is extremely low.
“This is not cause for alarm. Rather, it is evidence that the surveillance and response system we have in place is working,” said Melissa Sutton, M.D., medical director for respiratory viral pathogens at OHA.
“Our goal is to ensure that all symptomatic farm workers receive prompt testing and treatment to prevent severe disease. We appreciate the partnership with individuals on the farm during this challenging time.”
While the seasonal flu vaccine does not protect against HPAI, getting the seasonal flu vaccine can help reduce the risk of getting sick with human influenza viruses, which can, in turn, reduce the risk of co-infection with both a human seasonal virus and an avian virus, according to the Centers for Disease Control and Prevention (CDC).
In Oregon, public health has monitored more than 300 people exposed to sick animals since 2022; one human case of bird flu was identified in 2024 associated with a commercial poultry outbreak.
###
Source: US State of Oregon Department of Health, https://www.oregon.gov/oha/ERD/Pages/OHA-confirms-states-first-human-case-of-avian-influenza-of-2026-11.19.2026.aspx
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Abstract
Respiratory viral illnesses are common and can lead to severe outcomes, including hospitalization and death. U.S. trends in respiratory virus activity during July 2025–June 2026 were analyzed using data from six complementary public health surveillance systems. Respiratory syncytial virus (RSV) activity occurred unusually late in most U.S. regions. SARS-CoV-2 circulated nationally with typical bimodal peaks that occurred in August 2025 and January 2026. Annual RSV-associated hospitalization rates (number of hospitalizations per 100,000 persons) were highest among infants aged <12 months (790.2; 95% CI = 757.9–825.3), followed by children aged 12–23 months (611.9; 95% CI = 586.3–639.8) and adults aged ≥75 years (352.1; 95% CI = 309.9–407.7). Annual RSV rates overall and by age group did not exceed those observed during 2022–2025. COVID-19–associated hospitalization rates were highest among adults aged ≥75 years (361.2), infants aged <6 months (173.3), and adults aged 65–74 years (111.4). Newly established 2025–2026 national pediatric mortality surveillance provisionally identified 34 RSV-associated pediatric deaths from 35 reporting jurisdictions and 31 COVID-19–associated pediatric deaths from 43 reporting jurisdictions. RSV sequencing did not identify variant substitutions associated with reduced susceptibility to the available RSV monoclonal antibodies for infants. Most SARS-CoV-2 lineages were JN.1 descendants, but detections of BA.3.2, a highly divergent SARS-CoV-2 variant, increased. Circulation of other respiratory viruses followed usual historical patterns. Staying current with recommended RSV and COVID-19 vaccinations reduces the risk for severe illness and disease caused by these viruses.
Source: Morbidity and Mortality Weekly Report Journal, http://dx.doi.org/10.15585/mmwr.mm7545a2
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Abstract
Between August and October 2026, 49 autochthonous dengue cases were notified in Italy. Of these, 42 were exposed at a Tuscan coastal holiday site, and diagnosed after returning home, in 14 municipalities across seven provinces. Seven additional cases were identified, six in two areas where viraemic cases returned home and one near the holiday site. Dengue virus serotype 2, lineage 2II_F.1.1.5, was identified. When exposure occurs at holiday destinations, investigation and vector control should extend to places where cases reside.
© Creative Commons License. This work is licensed under a Creative Commons Attribution 4.0 International License.
Source: Eurosurveillance Journal, https://doi.org/10.2807/1560-7917.ES.2026.31.46.2600909
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Abstract
Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are zoonotic paramyxoviruses with high case fatality rates and pandemic potential. Despite their threat, no licensed vaccines are currently available for human use. Here, we present a structure-guided mRNA vaccine strategy that overcomes key challenges in antigen stability, fusogenicity, and cross-protective efficacy. Using rationally engineered NiV F glycoproteins stabilized in the prefusion conformation, we identify a lead candidate (F-205) that abolishes syncytium formation and elicits high prefusion-specific antibody titers. Through systematic combinatorial screening, we determine that co-delivery of F-205 (NiV-M) and G (NiV-B) antigens via mRNA–lipid nanoparticles induces potent neutralizing and cellular immune responses. In stringent golden hamster challenge models, this vaccine confers complete survival against lethal NiV-M, NiV-B and HeV challenge, with viral RNA undetectable in lung, spleen and brain after NiV challenge and significantly reduced viral burden after HeV challenge. We also introduce surrogate assays to assess F conformation and fusion activity under standard biosafety conditions, enabling iterative antigen optimization without live-virus handling. This study defines a broadly protective, mechanistically informed vaccine platform for HNVs and provides a generalizable framework for rational design of mRNA vaccines targeting class I fusion viruses.
Source: Nature Communications, https://doi.org/10.1038/s41467-026-79459-9
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Summary
Background
Uveitis is a known ocular manifestation in individuals who have survived Ebola virus disease (EVD). However, whether Ebola virus (EBOV; Orthoebolavirus zairense) persistence in vitreous fluid contributes to long-term sequelae of uveitis in EVD survivors remains unclear. We aimed to characterise the clinical findings and molecular and immunological findings in vitreous fluid from EVD survivors undergoing vitreoretinal surgery.
Methods
This cross-sectional study recruited EVD survivors (cohort 1), household close contacts of EVD survivors (cohort 2), and non-EVD patients with uveitis (cohort 3) from the Sierra Leone Ministry of Health’s Department of Ophthalmology or from the ongoing Sierra Leone Ministry of Health and the Lowell and Ruth Gess Eye Hospital Ebola Survivor Study (SMILE Study). EVD survivor status was based on an Ebola treatment unit certificate and confirmation in the Sierra Leone Association of Ebola Survivors registry, as well as an anti-EBOV assay. Close contacts of EVD survivors were individuals who lived in the same household as patients with EVD during the acute stage of the disease. Non-EVD patients with uveitis were individuals with vitreoretinal disease indications who were anticipated to benefit from surgical intervention. All patients had a comprehensive ophthalmic examination and pars plana vitrectomy with collection of vitreous fluid. These samples were investigated for molecular detection of EBOV RNA via quantitative RT-PCR (qRT-PCR) and evaluation of Goldmann–Witmer coefficients (GWCs) to identify intraocular production of EBOV-binding antibodies. Statistical analyses were performed to compare basic ophthalmic variables, demographic data, and GWC between the three groups.
Findings
From Jan 1, 2023, to Jan 1, 2024, a total of 25 patients (cohort 1 n=10, cohort 2 n=5, cohort 3 n=10) were enrolled. 13 (52%) patients were female, and median age was 39 years (IQR 34·0–53·5). The median time from EVD symptom onset to surgery was 108·5 months (IQR 103·8–110·8) in cohort 1, and the median time from close contact with a patient with EVD to surgery was 106·0 months (IQR 103·0–106·0) in cohort 2. EBOV RNA was detected by qRT-PCR in the vitreous fluid of two (20%) of ten EVD survivors. GWCs for EBOV glycoprotein IgG were significantly elevated (median 3·59, IQR 0·93–12·53, p<0·005 for between-group comparisons) in EVD survivors compared with those in close contacts (median 0, IQR 0–2·2) and patients with uveitis (median 0, IQR 0–0·62).
Interpretation
The detection of virus-specific immune responses and viral RNA at a median of 9 years after EVD diagnosis suggests long-term EBOV RNA persistence in the vitreous fluid of EVD survivors with vitreoretinal disease.
Funding
National Eye Institute of the National Institutes of Health, National Cancer Institute, National Institutes of Health, and Australian National Health and Medical Research Council.
Source: The Lancet Microbe, https://doi.org/10.1016/j.lanmic.2026.101547
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
{Summary}
{Click on Image to Enlarge}
___
Event description
The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo continues at a high and sustained level of transmission.
During epidemiological week 46 (9 – 15 November 2026), 442 confirmed cases and 239 confirmed deaths were reported, compared with 458 cases and 228 deaths in week 45; the national seven-day average has remained between 62 and 65 cases per day, and a new health zone, Watsa in Haut-UĂ©lĂ©, reported its first confirmed cases.
Over three epidemiological weeks (weeks 44 – 46 compared with weeks 41 – 43), reported cases decreased by 6.7% and deaths by 4.6%, with a decline in Ituri partly offset by continued intense transmission in Nord-Kivu, where Beni remains the health zone with the most cases, and by rising incidence in Mangala, Mambasa and Mutwanga.
Deaths in treatment centres increased in week 46 and the proportion of deaths occurring in the community fell to 59% (142 of 239), its lowest weekly level since August.
In Kenya, the last patient was discharged on 11 November, and all contacts have completed their follow-up; the 42-day countdown is under way, and the event has not yet been declared over.
In Nigeria, all 62 contacts completed their 21-day follow-up on 13 November and no secondary case was identified; surveillance continues in both countries.
Additionally, Nigeria started the 42 days countdown on 27 Oct after the case was medically evacuated to Switzerland on the 26 October 2026.
In the Democratic Republic of the Congo, insecurity in Beni, Mabalako and Bafwasende, strikes over unpaid salaries in several provinces and community resistance to safe burials continue to constrain surveillance and response operations.
Democratic Republic of the Congo
As of 15 November 2026, the BVD outbreak in the Democratic Republic of the Congo has affected 68 health zones and 248 health areas across eight provinces.
One new health zone, Watsa in Haut-Uélé, was affected during the reporting period (two confirmed cases reported on 11 November and seven on 13 November).
Since External Situation Report #26, (data as of 7 November), an additional 512 confirmed cases and 270 confirmed deaths have been reported between 8 and 15 November, of which 442 cases and 239 deaths during epidemiological week 46 (9 – 15 November).
The cumulative total is 11 432 confirmed cases, including 5 593 confirmed deaths [crude case fatality ratio (CFR) 48.9%].
Among cases with a documented outcome (5 593 deaths and 3 109 recoveries), the case fatality ratio is 64.3%; the outcome of the remaining 2 730 cases is still pending or not yet recorded.
Transmission remains highly heterogeneous across affected areas. Ituri continues to account for the largest proportion of cumulative confirmed cases (68.9%) and accounted for 227 of the 442 cases reported in week 46 (51.4%), while Nord-Kivu (25.3% of cumulative cases; CFR 55.4%) accounted for 169 (38.2%). Transmission persists at lower levels in Haut-Uélé (35 cases; 7.9%), Tshopo (10; 2.3%) and Nord-Ubangi (one case).
National daily incidence rose steadily from May to its highest levels in late July and mid-August, declined through late September and has fluctuated at a high plateau since early October. The seven-day moving average ranged between 62 and 65 confirmed cases per day during week 46 (63.1 on 15 November, compared with 65.4 on 8 November), well below the mid-August peak of 94 but with no downward trend over the last six weeks. Provincial trends diverged.
Ituri reported 227 cases in week 46 compared with 223 in week 45 (seven- day average of 32 cases per day on 15 November), with Mandima, Bunia, Mangala and Mambasa reporting the most cases, while Nord-Kivu reported 169 cases compared with 202 (24 cases per day on 15 November, down from 29 on 8 November), Beni still reporting the largest numbers in the province.
Haut-Uélé reported 35 cases compared with 24 (13 of them on 13 November, seven in the newly affected Watsa Health Zone), Tshopo 10 compared with six, and Nord- Ubangi one case in Wapinda. Bas-Uélé, Sud-Kivu and SudUbangi have reported no case in the last 21 days (Figures 1 and 2).
By week of symptom onset (Figure 3), confirmed cases recorded in the DHIS2 line list peaked between late July and mid-August, remained above 400 per week until mid September and have declined gradually since, to 370 in week 43 and 306 in week 44; weeks 44 to 46 are still incomplete because of the delay between symptom onset and reporting (median five days, 90th percentile 14 days).
{Click on Image to Enlarge}
___
(...)
Trend Analysis (21-day comparison):
During the most recent three epidemiological weeks (weeks 44 – 46, 26 October – 15 November 2026), a total of 1 369 confirmed cases were reported nationally, compared with 1 468 during the preceding 21 days (weeks 41 – 43, 5 – 25 October), a decrease of 99 cases (−6.7%).
Cases in Ituri decreased from 762 to 670 (−12.1%), accounting for 48.9% of national cases during the latest period, and in Nord-Kivu from 590 to 580 (−1.7%), accounting for 42.4%. Haut-UĂ©lĂ© increased from 77 to 90 cases (+16.9%; 6.6% of national cases) and Nord-Ubangi from three to four, while Tshopo decreased from 33 to 25 (−24.2%). Bas-UĂ©lĂ©, which reported three cases in the preceding period, reported none; SudKivu and Sud-Ubangi reported no case in either period. These weekly and three-week figures are sums of the daily counts published in the national sitreps, as on the COUSP dashboard; the corresponding differences in cumulative counts (1 372 and 1 457 cases) differ slightly because retrospectively added cases enter the cumulative totals only.
During the same period, 706 confirmed deaths were reported nationally, compared with 740 during weeks 41 – 43 (−4.6%). Deaths decreased from 402 to 355 (−11.7%) in Ituri, from 38 to 35 in Haut-UĂ©lĂ© and from 10 to eight in Tshopo, but increased from 289 to 308 (+6.6%) in Nord-Kivu, which now accounts for 43.6% of newly reported deaths (39.1% in the preceding period) against 50.3% for Ituri. Nord-Ubangi, which reported one death in the preceding period, reported none. In Nord-Kivu, deaths rose while cases fell slightly, consistent with the province's higher case fatality ratio (55.4%).
(...)
Transmission remained active in more than two-thirds of the health zones affected since the start of the outbreak. Of the 68 health zones affected to date, 48 (70.6%) in five provinces reported at least one new confirmed case during weeks 44 – 46 (26 October – 15 November): 21 in Ituri, 14 in Nord-Kivu, six in Haut-UĂ©lĂ©, five in Tshopo and two in NordUbangi. The comparison between the two 21 days periods covers the 54 health zones that reported at least one case in either period: incidence increased in 22, decreased in 28 and was unchanged in four (Mahagi and Nyankunde in Ituri, Alimbongo in Nord-Kivu and Wapinda in Nord-Ubangi); the remaining 14 zones reported no case in either period.
The largest absolute increase occurred in Beni, Nord-Kivu (228 to 273 cases; +19.7%), followed by Mutwanga, Nord-Kivu (28 to 71; +153.6%), Mangala, Ituri (22 to 63; +186.4%), Mambasa, Ituri (46 to 76; +65.2%), Oicha, Nord-Kivu (43 to 57; +32.6%), Mongbwalu, Ituri (10 to 22), Isiro, Haut-UĂ©lĂ© (7 to 18), Pawa, Haut-UĂ©lĂ© (19 to 29) and Masereka, Nord-Kivu (7 to 16). Watsa in Haut-UĂ©lĂ© (nine cases), Kilo (five), Drodro and Kambala (one each) in Ituri and Yakoma in Nord-Ubangi (four) reported cases after none in the preceding period (Figure 5). Conversely, the largest decreases were observed in Mandima (257 to 202), Rwampara (71 to 48), Bunia (170 to 149), Nia-Nia (27 to 8), Aru (17 to 1) and Komanda (18 to 2) in Ituri; Butembo (52 to 23), Katwa (61 to 36) and Mabalako (54 to 34) in Nord-Kivu; and Wamba (47 to 23) in HautUĂ©lĂ©. In week 46, Beni (71 cases), Mandima (65) and Bunia (51) reported the most cases, followed by Mangala (31), Oicha (25) and Mambasa (24). Zone-level figures are differences in cumulative confirmed cases between SitReps N°143, N°164 and N°185 and reconcile to the national totals.
There were 20 health zones without a new case during weeks 44 – 46: Adja, Ariwara, Aungba, Boga, Damas, Gety and Logo in Ituri; Goma, Kayna and Manguredjipa in Nord-Kivu; Dungu and Gombari in Haut-UĂ©lĂ©; Lubunga and WanieRukula in Tshopo; Miti-Murhesa in Sud-Kivu; Buta, Dakwa, Ganga and Viadana in Bas-UĂ©lĂ©; and Bulu in Sud-Ubangi. Six of them (Damas, Gety and Logo in Ituri, Manguredjipa in Nord-Kivu, and Dakwa and Ganga in Bas-UĂ©lĂ©) had reported cases during weeks 41 – 43.
(...)
Weekly confirmed deaths (Figure 7) have fluctuated between 220 and 290 since mid-October: 286 in week 43 (19 – 25 October), 239 in week 44, 228 in week 45 and 239 in week 46 (9 – 15 November), an increase of 4.8% over the preceding week. Community deaths decreased from 149 in week 45 to 142 in week 46 while deaths in treatment facilities rose from 79 to 97, so that the proportion of deaths occurring in the community fell from 65.4% to 59.4%, the lowest weekly share since the week of 17 – 23 August (Figure 8). On 15 November, 18 of the 25 confirmed deaths (72%) occurred in the community. Although the shift in week 46 suggests that more patients reached treatment facilities before dying, three in five confirmed deaths still occur outside treatment facilities, and the increase in deaths in treatment centres also points to late presentation.
(...)
Kenya
Since the previous report, Kenya has reported no new confirmed case of BVD. The cumulative total remains nine confirmed cases, including two deaths (CFR 22.2%), all belonging to a single chain of transmission linked to the imported index case; the last confirmed case was reported on 19 October 2026.
On 11 November 2026, the Ministry of Health announced the discharge of the last patient under treatment, the seventh survivor, after two consecutive negative tests, and the final 11 contacts completed their 21-day monitoring and were released from quarantine on the same day. For the first time since the first case was confirmed, Kenya has no patient under treatment and no contact under follow-up.
The 42-day countdown started on 12 November 2026; the end of the event will be declared by the Government if no new case is detected during that period. Surveillance, screening at points of entry and survivor follow-up continue.
(...)
Nigeria
Nigeria has reported a single confirmed case of BVD, confirmed on 20 October 2026 in the Federal Capital Territory, Abuja, in a traveller from Uganda. The patient was medically evacuated to Switzerland on 26 October and discharged from the Geneva University Hospitals on 11 November 2026 after full recovery; the 42-day countdown is counted from 27 October, the day after the evacuation. No secondary case has been identified. On 13 November 2026, the Nigeria Centre for Disease Control and Prevention (NCDC) announced that all 62 contacts of the index case had completed their 21-day follow-up; 13 contacts who developed fever or non-specific symptoms during monitoring tested negative, as did seven suspected cases reported from Adamawa, Borno, Ekiti, Lagos and Rivers states over the preceding three weeks.
The 62 contacts include the companion evacuated with the patient, whose follow-up in Switzerland was due to end on 16 November according to the Swiss IHR National Focal Point. The Emergency Operations Centre remains activated and surveillance continues; the completion of contact monitoring does not constitute a declaration of the end of the event, which will follow WHO criteria.
Two lessons stand out from this event: the rapid activation of the incident management system and of response activities once the case was notified and confirmed, and the 12-day interval between symptom onset and notification, eight days of which were spent in a private health facility, which underlines the need for a high index of suspicion among clinicians for travellers from affected areas.
(...)
Situation interpretation
The BVD outbreak in the Democratic Republic of the Congo remains at a critical juncture six months after its declaration.
Transmission is broadly stable at a high level: 442 confirmed cases and 239 deaths were reported in epidemiological week 46, the national seven-day average has held between 61 and 76 cases per day since the beginning of October, and the three-week totals fell marginally, from 1 468 to 1 369 cases (−6.7%) and from 740 to 706 deaths (−4.6%).
The decrease is driven by Ituri, where Mandima, Bunia and Rwampara reported fewer cases, while Mangala and Mambasa in Ituri and Mutwanga and Oicha in Nord-Kivu are intensifying, Beni remains the largest focus, Haut-Uélé reported a new health zone (Watsa), and sporadic transmission continued in Tshopo and Nord-Ubangi.
The response is still not reaching the performance required to interrupt transmission: only half of investigated suspected cases are isolated within 24 hours, close to one in six contacts is not seen each day, more than 1 000 contacts have been lost to follow-up, and three in five deaths still occur in the community, although the share of community deaths fell in week 46 and safe burial refusals decreased.
Insecurity in Beni, Mabalako and Bafwasende, strikes over unpaid salaries and shortages of vaccine doses in Nord-Kivu further constrain operations.
In Kenya, where eight secondary cases occurred in a single chain, all contacts have completed follow-up and the 42-day countdown is under way; in Nigeria, contact monitoring 18 ended on 13 November with no secondary case identified.
Neither event has been declared over and surveillance continues in both countries. Priorities remain reinforcing response capacity in the most active health zones of Nord-Kivu (Beni, Mutwanga, Oicha) and Ituri (Mandima, Bunia, Mangala, Mambasa), investigating the new focus in Watsa, improving the timeliness of isolation of suspected cases and the completeness of contact follow- up, maintaining safe burial performance, securing vaccine supply for frontline workers, and maintaining cross-border surveillance and information sharing.
Source: World Health Organization, Regional Office for Africa, https://www.afro.who.int/countries/kenya/publication/ebola-bundibugyo-virus-disease-outbreak-democratic-republic-congo-uganda-weekly-external-situation
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Abstract
Public health recommendations often advise people to isolate when infected with influenza-like illness (ILI) with the goal of promoting physical distancing and limiting face-to-face interactions when risk of transmission is highest. Because isolation may have negative consequences, it is important to carefully assess whether encouragement to physically distance actually prevents cases of ILI. College campuses can be especially vulnerable to outbreaks of ILI and are ideal environments for assessing the impact of encouragement-to-physically-distance interventions. The eX-FLU cluster-randomized trial followed 579 students on a college campus over a ten-week period during flu season to evaluate such an intervention. Students in the trial were randomized to receive the intervention—encouragement to isolate in their dorm room when symptomatic for ILI—or control. Evaluating the effect of this intervention is challenging because of dependence between students in the trial and an anticipated spillover effect of the intervention. Moreover, while the intervention was designed to affect both face-to-face interactions and ILI infections, the effect on ILI infections is of primary public health interest. In this paper, a randomization-based testing procedure is proposed to assess the intervention effect specifically on ILI infections in the presence of dependent data and spillover effects. The testing procedure is shown theoretically and empirically to control the type I error rate and have good statistical power to detect an intervention effect in trials similar to eX-FLU. When applied to the eX-FLU data, this testing procedure gives moderate evidence that the intervention reduced ILI infections.
Source: Proceedings of the National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.2626810123
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Abstract
Surveillance of viruses in swine depends largely on the sampling of individual animals chosen at random, often limiting detection breadth. Environmental sampling has emerged as an alternative strategy, enabling faster, safer and more cost-effective pathogen monitoring at the human-animal interfaces. Across nine visits to two Cambodian slaughterhouses, we applied metagenomic sequencing to air samples (n = 25), faeces (n = 156), wastewater (n = 15), carcass wash water (n = 18), holding-pen swabs (n = 124), slaughter-box swabs (n = 73) and ropes (n = 16), comparing virus composition to pig snout swabs (n = 193). Combined environmental sampling recovered 96.6% of the viral taxa detected in snout swabs, exceeding 90.9% at every visit. Greater viral diversity was consistently captured in the environment, including swine-associated taxa absent from snout swabs and viral RNA associated with avian and human hosts. Air provided the widest coverage of any single environmental sample type and contributed the largest number of independent virus detections that were not recovered from any other environmental sample. Slaughter-box swabs recovered the fewest taxa, showing that visible contamination with swine material did not correlate with greater viral recovery. Overall, this study identifies air as a pivotal core component of any surveillance program. However, pairing air with additional environmental sample types provides the broadest virus coverage and represents the optimal surveillance strategy in swine slaughterhouses.
Competing Interest Statement
The authors have declared no competing interest.
Funder Information Declared
Gates Foundation, INV-049293
National Institute of Allergy and Infectious Diseases, 12-312-0217530, 1U01AI151378-01, 75N93021C00016
Food and Agriculture Organization of the United Nations
Duke-NUS Signature Research Programme
National Research Foundation, Singapore, FY2025-NRF-PA-0002
Source: BioRxIV, https://doi.org/10.64898/2026.11.16.765117
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.
Situation at a glance
On 4 November 2026, health authorities in the canton of Ticino, Switzerland, in coordination with federal authorities, reported four locally acquired cases of chikungunya virus disease.
These are the first reported locally acquired chikungunya cases in Switzerland.
The earliest reported symptom onset was 10 August 2026, although this infection was identified retrospectively and the source of infection could not be identified.
All cases were identified in October 2026.
None of the affected individuals reported recent travel to areas with known chikungunya virus transmission, and all four resided in the same geographically defined area.
All cases had a favourable clinical course, although joint symptoms persisted in some individuals.
The Asian tiger mosquito (Aedes albopictus), a competent vector for chikungunya virus, is established in several Swiss cantons, including Ticino.
Public health authorities have implemented active case finding, enhanced health care-provider awareness, entomological investigations, targeted vector-control interventions and risk communication.
No additional suspected cases were identified through enhanced surveillance and active case finding among health care providers and the two emergency departments serving the affected area.
Based on the currently available information and the seasonal decline in mosquito activity, the risk of further local transmission is considered low.
However, the event demonstrates that local chikungunya transmission is possible in Switzerland following introduction of the virus into areas where competent Aedes mosquito populations are established.
Description of the situation
On 4 November 2026, health authorities in the canton of Ticino, Switzerland, in coordination with federal authorities, reported four locally acquired cases of chikungunya virus disease.
The earliest reported symptom onset was 10 August 2026. This infection was identified retrospectively, and the source of infection is not known.
The first laboratory-positive case was detected on 9 October through positive chikungunya virus-specific immunoglobulin M (IgM) serology.
Additional cases were identified and confirmed on 13, 22 and 23 October.
Laboratory investigations included chikungunya virus-specific serological testing and molecular detection by polymerase chain reaction (PCR).
Three cases tested positive for chikungunya virus-specific IgM antibodies, including one that was also PCR-positive, while the fourth case tested positive for chikungunya virus-specific Immunoglobulin G (IgG) antibodies.
None of the four individuals reported recent travel to areas with known chikungunya virus transmission.
They resided in the same geographically defined area. Their spatial and temporal proximity, together with the absence of recent travel, strongly suggests locally acquired mosquito-borne infection. However, a common source or direct epidemiological link between all cases could not be established.
All four individuals had a favourable clinical course and were in good health at the time of reporting, although joint symptoms persisted in some cases.
Active case finding among health care providers and local emergency departments did not identify additional suspected cases.
Entomological investigations were conducted in the affected area. A relatively low abundance of Ae. albopictus was observed, and chikungunya virus ribonucleic acid (RNA) was not detected by reverse transcription polymerase chain reaction (RT-PCR) in the mosquitoes that were collected and tested. These negative results do not exclude local transmission.
The detection of locally acquired infections in Switzerland was concurrent with locally acquired chikungunya transmission elsewhere in Europe during summer and autumn 2026.
As of 4 November 2026, France had reported 207 locally acquired cases.
Italy had reported one locally acquired case in Rome, with symptom onset in August.
Epidemiology
Chikungunya is a mosquito-borne viral disease caused by chikungunya virus, an RNA virus belonging to the Alphavirus genus of the family Togaviridae.
The virus is transmitted to humans primarily through the bites of infected female Aedes aegypti and Aedes albopictus mosquitoes. These mosquito species can also transmit other arboviruses, including dengue and Zika viruses, and bite primarily during daylight hours.
Symptoms generally develop 4 to 8 days after the bite of an infected mosquito, although the incubation period can range from 2 to 12 days.
Chikungunya is characterized by an abrupt onset of fever, frequently accompanied by severe joint pain. Other symptoms may include joint stiffness, arthritis, headache, fatigue and rash. Most patients recover fully, but joint pain can persist for weeks, months or, in some cases, years.
Severe disease and deaths are uncommon but may occur, particularly among newborns infected around the time of birth, older adults and people with underlying health conditions.
There is no specific antiviral treatment for chikungunya virus infection. Clinical management is symptomatic and supportive, with particular attention to pain management.
Chikungunya continues to pose a public health threat across WHO regions in 2026. From 1 January through 30 September 2026, 327 086 cases, including 83 660 confirmed cases and 98 deaths, were reported globally, according to the WHO global chikungunya surveillance dashboard. The WHO Region of the Americas and the WHO South-East Asia Region accounted for the largest proportions of reported cases.
Public health response
The Cantonal Medical Office in Ticino, in collaboration with the University of Applied Sciences and Arts of Southern Switzerland, municipal authorities and the relevant federal authorities, has implemented the following measures:
° Epidemiological investigation and active case finding:
§ A broader epidemiological investigation was initiated on 22 October 2026 following identification of the third case.
§ Health care providers practising in the affected area and the two emergency departments serving the local population were contacted to increase awareness and facilitate the detection of potentially unrecognized infections.
§ An official communication was subsequently distributed to all practising physicians in Ticino, encouraging increased clinical vigilance.
§ No additional suspected cases were identified through active case finding.
° Vector-control measures:
§ Targeted vector-control measures began on 26 October and included door-to-door interventions, such as to kill adult mosquitoes and treatment of standing water to kill larvae.
§ These emergency interventions supplemented the routine mosquito-control programme implemented throughout Ticino.
° Entomological surveillance:
§ Mosquitoes collected in the affected area were tested by RT-PCR, with no chikungunya virus RNA detected.
§ Established entomological surveillance continues at multiple monitoring sites in Ticino.
° Risk communication and prevention:
§ Public communication activities were implemented to increase awareness among the general population and health care professionals.
§ Messages emphasized personal protection against mosquito bites and continued action to prevent and control Ae. albopictus.
§ Travellers returning from affected areas were advised to protect themselves from mosquito bites for 14 days after their return to reduce the possibility of onward local transmission.
WHO risk assessment
The public health impact of the currently reported event in Switzerland is expected to be limited.
Four locally acquired cases were identified within a geographically defined area. All four individuals had a favourable clinical course, and no additional suspected cases were identified despite active case finding and enhanced epidemiological surveillance.
No evidence of sustained local transmission has been identified.
The occurrence of the first documented locally acquired chikungunya virus infections in Switzerland demonstrates that local transmission is possible following introduction of the virus into areas where competent Ae. albopictus populations are established. This highlights the importance of maintaining clinical awareness, surveillance, preparedness, early diagnosis and appropriate case management.
The likelihood of sustained transmission is influenced by seasonal and climatic conditions affecting mosquito abundance, survival and vector competence. Climatic conditions in Ticino during summer 2026 were highly favourable for Ae. albopictus development and virus transmission, particularly in August, when the earliest suspected locally acquired infection is likely to have occurred. By early October, when the other cases were detected, meteorological conditions were considerably less favourable for mosquito development and activity.
As mosquito activity typically decreases with the progression of autumn, the risk of further transmission is considered low under the current epidemiological and seasonal conditions, and additional locally acquired cases are considered unlikely. The presence of established competent vectors means that future introductions by infected travellers could lead to localized transmission during periods of mosquito activity.
The established Ae. albopictus surveillance and control programme in Ticino, which has been in place since 2000, has maintained relatively low and stable mosquito densities and is considered an important factor limiting the potential for local transmission and spread. Over the longer term, changes in temperature, precipitation and seasonality may expand the geographical areas and periods suitable for Ae. albopictus and Aedes-borne virus transmission in Switzerland.
WHO advice
WHO recommends that affected and unaffected States Parties, particularly those where competent Aedes vectors are established, maintain epidemiological surveillance and laboratory capacity for the timely detection and confirmation of chikungunya virus infection. Epidemiological and entomological surveillance should be integrated with timely vector-control measures around suspected or confirmed locally acquired cases.
Prevention and control measures should focus on reducing mosquito breeding sites and protecting people against mosquito bites. Recommended measures include wearing clothing that minimizes skin exposure, applying appropriate mosquito repellents in accordance with product instructions, and using physical barriers where appropriate.
People with suspected or confirmed chikungunya virus infection should avoid mosquito bites during the viraemic period to reduce the possibility that mosquitoes acquire the virus and subsequently transmit it to other people.
Travellers to areas with chikungunya virus transmission should take precautions against mosquito bites. Travellers returning to areas where competent vectors are established should continue to protect themselves against mosquito bites after their return to reduce the risk of introducing the virus into local mosquito populations.
Chikungunya vaccines have received regulatory approval in several countries, although vaccine availability and national recommendations vary. In Switzerland, Vimkunya® has been authorized since April 2026 for people aged 12 years and older. According to Swiss recommendations, vaccination is recommended for travellers to areas abroad experiencing an ongoing chikungunya outbreak and may be considered for prolonged or repeated stays in areas with an increased risk of chikungunya following an individual risk assessment.
Based on the currently available information, WHO advises against any restriction of travel to, or trade with, States Parties experiencing or responding to the public health event.
Further information
° World Health Organization. Chikungunya fact sheet. Updated 14 April 2025. https://www.who.int/news-room/fact-sheets/detail/chikungunya
° World Health Organization. Global chikungunya surveillance. Updated 13 October 2026. https://worldhealthorg.shinyapps.io/chikungunya_global/
° World Health Organization. Rapid Risk Assessment: Chikungunya virus disease, Global, version 2. Published 1 May 2026. https://www.who.int/publications/m/item/who-rapid-risk-assessment---chikungunya-virus-disease--global-v.2
° European Centre for Disease Prevention and Control. Seasonal surveillance of chikungunya virus disease in the EU/EEA – 2026. Updated 30 October 2026. https://www.ecdc.europa.eu/en/public-health-events/2026-evd-00016/2026-10-30
° European Centre for Disease Prevention and Control. Invasive mosquitoes: surveillance and distribution maps. Updated 3 June 2026. https://www.ecdc.europa.eu/en/disease-vectors/surveillance-and-disease-data/invasive-mosquito-maps
° Swiss Federal Office of Public Health. Chikungunya. Accessed 11 November 2026. https://www.bag.admin.ch/en/chikungunya
° Goepp L, Riou J. Projecting the future risk of Aedes-borne diseases in Switzerland. NCCS-Impacts, February 2026. https://www.bag.admin.ch/dam/de/sd-web/88JGcdvj6ijJ/EN_NCCS_Factsheet_4.2_final.pdf
° Repubblica e Cantone Ticino, Dipartimento della sanitĂ e della socialitĂ . Quattro casi autoctoni di febbre Chikungunya in Ticino – rischio attuale molto basso. Published 4 November 2026. https://www4.ti.ch/tich/area-media/comunicati/dettaglio-comunicato?NEWS_ID=261508&cHash=e51a19616b794a18582fd1af6ba53b78
° Walss M, Haase-Meneghetti C, Sydow V, et al. Chikungunya case cluster with nonspecific symptoms: implications for primary care in Switzerland. Swiss Med Wkly. 2026;156:5575. https://doi.org/10.57187/5575
Citable reference: World Health Organization (17 November 2026). Disease Outbreak News; Chikungunya in Switzerland. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON627
Source: World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON627
____
I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.